Ambuja Cements reported strong Q2 FY26 results, driven by 20% volume growth and improved cost efficiencies. EBITDA reached INR1,060 per metric ton, a 32% year-over-year increase. The company is targeting a capacity of 155 million tons by FY28 through debottlenecking and strategic expansions. Green Power share increased to 33%, with plans to reach 60% by FY28. Ambuja Cements maintains a bullish outlook on cement demand.

Financial Performance Highlights

Ambuja Cements reported a strong financial performance for Q2 FY26, demonstrating robust growth and improved profitability:

• Highest ever sales volume in Q2 at 16.6 million tons, up 20% year-over-year.
• Revenue increased by 21% year-over-year to INR9,174 crores.
• EBITDA reached INR1,761 crores, a 58% year-over-year increase.
• EBITDA margin stood at 19.2%, up from 14.7% in the previous year.
• Profit after tax was INR2,302 crores, up 364%.

Strategic Initiatives and Expansion

Ambuja Cements is undertaking several strategic initiatives to drive future growth and efficiency:

• Capacity expansion target revised to 155 million tons by FY28, with clinker capacity increasing to 96 million tons.
• Debottlenecking initiatives adding 15 million tons of capacity at a capex of $48 per ton.
• Logistics improvements expected to reduce lead distance by another 50 kilometers.
• Green Power share increased to 33% in Q2, targeting 60% by FY28.

Cost Reduction and Efficiency Measures

The company is focused on cost leadership and efficiency improvements:

• Total costs reduced by 5% year-over-year, led by kiln fuel cost at INR1.65 per 1,000-kilo calories.
• Targeting total cost of ~ INR4,000 per metric ton by the end of FY26.
• Logistics cost down by almost 7% year-over-year at INR1,224.

Operational Excellence and Sustainability

Ambuja Cements is committed to operational excellence and sustainability:

• Green Power share has increased to 33%. Renewable energy capacity is expected to reach almost 900-megawatt by the end of the financial year and 1,122 megawatts by FY ’27.
• Signed an MOU with Coolbrook of Finland.

Industry Outlook

Ambuja Cements remains bullish on cement demand, expecting industry growth of 7% to 8%. The company is well-positioned to capitalize on improved economic sentiment and higher investments in both public and private sectors.

Source: BSE

Action Construction Equipment Limited (ACE) has announced the availability of the audio clip for its Q2FY-2026 conference call, which took place on November 07, 2025. The audio clip provides insights into the company’s performance and outlook. Investors and stakeholders can access the audio recording through the provided link to gain detailed information about the discussions held during the call.

Q2FY26 Conference Call Audio Recording

Action Construction Equipment (ACE) has released the audio recording of its conference call for the second quarter of fiscal year 2026 (Q2FY26). The conference call, held on November 07, 2025, covered the company’s financial results and operational highlights for the quarter.

Accessing the Audio Clip

The audio clip is now available for replay, enabling investors and analysts to review the discussions and gain further insights into the company’s performance. To access the audio recording, please use the following link:

Audio Clip Link

Key Discussion Points

The conference call featured management commentary on various aspects of the business, including market trends, financial performance, and strategic initiatives. Q2FY26 provides key information about ACE’s operational execution, market dynamics, and future growth strategies.

Source: BSE

Anand Rathi Wealth Limited announces with profound sorrow the sudden demise of Mr. Chethan Shenoy, Head of Product & Research, on November 8, 2025, due to cardiac arrest. Mr. Shenoy’s contributions and leadership were integral to the company’s growth, and his loss will be deeply felt by employees, clients, and stakeholders. The company extends its heartfelt condolences to his family.

Sudden Passing of Key Executive

It is with deep regret that Anand Rathi Wealth Limited announces the untimely passing of Mr. Chethan Shenoy, who served as the Head of Product & Research. His demise occurred on November 8, 2025, due to a cardiac arrest.

Impact and Condolences

Mr. Shenoy’s dedication and strong leadership were invaluable to the company. His contributions played a significant role in the growth and success of Anand Rathi Wealth Limited. The company mourns his loss and extends its deepest sympathy to his family during this difficult time.

Details of Demise

The announcement confirms that Mr. Shenoy’s passing is classified as a death as per regulatory requirements.

Source: BSE

Shyam Metalics reported strong financial results for Q2 & H1 FY26. Revenue grew by 23% in Q2. The company highlighted operational efficiencies and strategic expansions contributing to higher ROCE and lower CAPEX requirements. They also emphasized focus on value-added products and deleveraging the balance sheet to provide flexibility in growth. PAT positive since 2005.

Financial Performance Highlights

Shyam Metalics announced a strong financial performance for the second quarter and first half of fiscal year 2026:

• Q2 FY26:

Revenue: Rs. 4,457 Cr, EBITDA: Rs. 609 Cr, PAT: Rs. 260 Cr.

Revenue growth in Q2 was reported at 23% and volume growth at 24%.

• H1 FY26:

Revenue: Rs. 8,876 Cr, EBITDA: Rs. 1,242 Cr, PAT: Rs. 551 Cr.

Strategic Growth & Expansion

The company is focused on strategically expanding into diversified, value-added product segments. A key focus is on increasing capacity in a cost-effective manner. Some key initiatives:

• Expanding into value-added product segments with higher ROCE and lower CAPEX.
• Continued focus on operational efficiencies to drive profitability.
• Maintaining a conservative capital structure with debt to equity capped at 0.5x.

Capital Expenditure & Projects

Shyam Metalics has committed to funding CAPEX through internal accruals. Capex incurred till Q2 FY26 reached Rs. 7,529 crores, representing 80% of total envisaged CAPEX.

Credit Rating

The company’s long-term credit rating has been upgraded to CRISIL AA+ (Stable), the highest among peer groups, reflecting a strong financial risk profile.

Source: BSE

Poly Medicure announced its unaudited financial results for the second quarter of FY26. Consolidated revenue grew by 5.7%, with domestic revenue up by 16.9%. The company completed acquisitions of PendraCare Group and Citieffe Group. Operating EBITDA margin stood at 26.8%. The company maintains a strong liquidity position with ₹1,109.1 Crs in net cash as of September 30, 2025.

Financial Performance

Poly Medicure reported a consolidated revenue growth of 5.7% for Q2 FY26, with domestic revenue showing a stronger growth of 16.9%. The Operating EBITDA margin for the quarter was 26.8%.

Key Highlights for Q2 FY26

• Completed acquisitions of PendraCare Group (Netherlands – Cardiology) and Citieffe Group (Italy – Orthopaedics).
• Launched “Polymed Academy of Clinical Excellence” (PACE).
• Launched 8 new products.

Consolidated Financial Results Summary

Key figures for Q2 FY26 (July-September):

• Revenue from Operations: ₹443.9 Crs (up 5.7% year-over-year)
• Gross Profit: ₹308.2 Crs (up 7.2% year-over-year)
• Operating EBITDA: ₹118.8 Crs (up 2.5% year-over-year)
• PAT: ₹91.8 Crs (up 5.0% year-over-year)

Balance Sheet Highlights

• Net Cash: ₹1,109.1 Crs as of September 30, 2025

Segment Performance

• Infusion Therapy: ₹273.5 Crs
• Renal: ₹44.2 Crs
• Others: ₹125.9 Crs

Shareholding Pattern

As of September 30, 2025:

• Promoters & Promoter Group: 62.4%
• Foreign Portfolio Investors: 9.8%

Source: BSE

Apollo Hospitals Enterprise Limited has received in-principle approval from the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) for issuing and allotting a maximum of 21,56,770 equity shares under its Employee Stock Option Plan 2024. These shares, valued at Rs. 5/- each, will be offered to eligible employees of the company, reinforcing its commitment to employee welfare.

ESOP Approval Granted

Apollo Hospitals Enterprise Limited announced that it has secured in-principle approval from both the BSE and NSE for its Employee Stock Option Plan (ESOP) 2024. This approval allows the company to proceed with issuing and allotting shares to its employees under the terms of the plan.

Details of the ESOP

The approval covers a maximum of 21,56,770 equity shares, each with a face value of Rs. 5/-. These shares are intended to be allotted to the company’s employees as part of the Apollo Hospitals Enterprise Limited Employee Stock Option Plan 2024 (Apollo ESOP 2024).

Official Communication

The company officially communicated that the approval letters from BSE (reference number DCS/ESOP/IP/TS/3877/2025-26) and NSE (reference number NSE/LIST/51179), both dated November 7, 2025, have been received. These approvals mark a significant step forward in the implementation of the ESOP, allowing the company to reward and incentivize its employees through equity participation.

Source: BSE